Concerned over the recent takeover of some firms by Multi National Companies (MNCs), the domestic pharmaceutical industry has asked the government to protect and promote it by making available funds for research and development.
In a letter to the department of pharmaceuticals, Indian Pharmaceutical Alliance (IPA) has said lack of available funding is the main reason for the recent spurt in the sale of stakes in domestic companies.
"In view of your concern and interest in promoting growth and development of pharmaceutical industry, we urge you to examine this phenomenon and consider appropriate funding mechanism to protect and promote the domestic industry," IPA said.
Since June last year, multinationals have acquired six drug comopanies, including the Rs 22,000 crore takeover of Ranbaxy Laboratories by Japanese drug maker Daiichi Sankyo.
According to industry experts, drying up of product pipelines of MNCs are forcing them to buy up Indian firms to a get a hold on the generic business globally. Of late, there have been reports of majors like Pfizer scouting the Indian market for acquisitions.
The association said the sell-outs have highlighted the need for an "appropriate funding mechanism" to meet the challenges faced by Indian pharma companies.
Also, these have exposed the limitations of the current policy framework of providing weighted deduction for R&D and meagre amounts granted under Market Development Assistance (MDA) programme, it said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
